HWHG(SH:600079) Ge Long Hui A P P·2025-11-06 08:44Core Viewpoint - The company, Renfu Pharmaceutical, has received approval from the National Medical Products Administration for the clinical trial of HWH217 tablets, aimed at treating Group 1 pulmonary arterial hypertension, marking a significant step in its drug development pipeline [1] Company Summary - Renfu Pharmaceutical's wholly-owned subsidiary, Hubei Biopharmaceutical Industry Technology Research Institute, has been granted a clinical trial approval notice for HWH217 tablets [1] - HWH217 is classified as a chemical drug of category 2.3 and is a new compound formulation containing known active ingredients [1] - The clinical trial application for HWH217 was accepted on August 15, 2025, and is intended for the treatment of pulmonary arterial hypertension, specifically for WHO Group 1 [1] - The total research and development investment for this project has reached approximately 6 million RMB [1] Industry Summary - Currently, there are no approved compound formulations in China for the treatment of the specified indication, indicating a potential market opportunity for HWH217 [1]